BioSpace News Archive

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST in New York City.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Thursday, March 3, 2022, at 8:30 a.m. ET.

Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced today that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement.

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees at the SACHS 15th Annual European Life Sciences Virtual CEO Forum taking place March 1-2, 2022.

BioAdaptives, Inc. (OTCMkts: BDPT), In reference to the previous Press Release of February 24, 2022, the Company announced today that it will continue providing Pluripain® and monitoring the use of this product by those suffering from the symptoms of Gadolinium Deposition Disease (GDD).

IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification technology.

Two studies on COVID-19 patients were conducted in Field Hospital No. 3 by Traditional Medicine Institute of Ho Chi Minh City.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.95 per share on its outstanding shares of Common Stock.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA approved inducement grants of stock options to purchase an aggregate of 63,800 shares of its common stock to 17 newly-hired employees, with a grant date of February 23, 2022.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that on February 22, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 158,500 shares of its common stock to eight employees as a material inducement for each employee’s entry into employment with TransMedics.